{"nctId":"NCT01541371","briefTitle":"A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia","startDateStruct":{"date":"2008-07"},"conditions":["Schizophrenia"],"count":405,"armGroups":[{"label":"Paliperidone ER","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone ER"]}],"interventions":[{"name":"Paliperidone ER","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis criteria of schizophrenia\n* Participant receiving full course of treatment (6-8 weeks) at correct dose (dose range recommended by the instruction) of Risperdal, Zyprexa or Seroquel before enrollment, was poorly controlled and had to change medication because of unsatisfying efficacy, tolerability or safety issues, or other reason\n* Participant in the non-acute phase during screening received treatment with any of above three antipsychotics within 4 weeks before enrollment and state of illness was relatively stable\n* 7\\. Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study. Effective methods of birth control include prescription hormonal contraceptives, contraceptive injections, intrauterine devices, double barrier method, contraceptive patch and male partner sterilization. Female participants must also have a negative urine pregnancy test at screening\n* Participant willing to and who could complete questionnaire by himself\n\nExclusion Criteria:\n\n* Participant receiving treatment with clozapine or risperidone microspheres for injection (Hengde) within 3 months before screening\n* Participant having history of seizure except febrile convulsion (seizures that occur during a febrile episode \\[fever\\])\n* Participant having refractory schizophrenia (previous treatment with unsatisfied efficacy of 2 or more than 2 kinds of antipsychotics with different chemical structure after adequate dose and duration)\n* Participant receiving electric shock treatment within 1 month before screening\n* Participant having serious, unstable physical diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12","description":"PANSS is a medical scale that assesses various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions \\[a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder\\] and hallucinations \\[imagining things\\], and withdrawal into the self). The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.18","spread":"17.50"},{"groupId":"OG001","value":"58.46","spread":"16.31"},{"groupId":"OG002","value":"63.33","spread":"19.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.29","spread":"20.77"},{"groupId":"OG001","value":"-13.99","spread":"15.74"},{"groupId":"OG002","value":"-20.90","spread":"18.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Subscale Scores at Week 12","description":"PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Positive syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. Negative syndrome subscale ranges from 7 to 49, higher change scores indicate worsening. General Psychopathology subscale ranges from 16 to112, higher change scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.07","spread":"6.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.59","spread":"6.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.57","spread":"6.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"5.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.44","spread":"9.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.84","spread":"10.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Subscale Scores at Week 12","description":"The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). Positive symptoms subscale consists of 8 items with total score range of 8-56; negative symptoms subscale and disorganized thoughts subscale, each consists of 7 items with total score range of 7-49, uncontrolled hostility/excitement subscale and anxiety/depression subscale, each consists of 4 items with total score range of 4-28. Higher change score indicates greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.61","spread":"7.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.16","spread":"7.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.15","spread":"7.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.53","spread":"6.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.13","spread":"4.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.13","spread":"4.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.73","spread":"3.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.74","spread":"3.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.45","spread":"2.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"2.67"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Response to Positive and Negative Syndrome Scale (PANSS) Total Score","description":"PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Percentage of participants with at least 20 percent improvement of PANSS total score was measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.97","spread":null},{"groupId":"OG001","value":"51.72","spread":null},{"groupId":"OG002","value":"61.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Week 12","description":"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"normal, not at all ill\" and a rating of 7 is equivalent to \"among the most extremely ill participants\". Higher change scores indicate worsening.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.54","spread":"0.91"},{"groupId":"OG001","value":"3.20","spread":"1.11"},{"groupId":"OG002","value":"3.86","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.77","spread":"0.09"},{"groupId":"OG001","value":"-1.01","spread":"0.14"},{"groupId":"OG002","value":"-1.66","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Personal and Social Performance (PSP) Score at Week 12","description":"PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 6, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\\<30, functioning so poorly as to require intensive supervision.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.16","spread":"13.79"},{"groupId":"OG001","value":"66.95","spread":"12.89"},{"groupId":"OG002","value":"66.00","spread":"11.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.57","spread":"16.87"},{"groupId":"OG001","value":"10.09","spread":"13.75"},{"groupId":"OG002","value":"12.40","spread":"13.33"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Satisfaction With the Study Treatment","description":"Participants assessed their satisfaction with paliperidone ER on a 5-point scale: 1 (very good), 2 (good), 3 (moderate), 4 (poor) and 5 (very poor).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sleep and Daytime Drowsiness Evaluation Score at Week 12","description":"The self-administered sleep VAS scale (0-100 milimeter \\[mm\\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.76","spread":"26.70"},{"groupId":"OG001","value":"75.89","spread":"20.24"},{"groupId":"OG002","value":"70.31","spread":"22.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.76","spread":"29.46"},{"groupId":"OG001","value":"2.90","spread":"27.41"},{"groupId":"OG002","value":"13.60","spread":"26.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.16","spread":"23.70"},{"groupId":"OG001","value":"44.77","spread":"25.29"},{"groupId":"OG002","value":"34.26","spread":"23.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.76","spread":"27.52"},{"groupId":"OG001","value":"-21.66","spread":"27.88"},{"groupId":"OG002","value":"-18.10","spread":"26.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":403},"commonTop":["Akathisia","Tremor","Dystonia","Somnolence","Insomnia"]}}}